Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Oral Azacitidine (CC-486) in Hematological Disorders
2023-503272-25-00Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in Hematopathy, sponsored by Celgene Corporation. Primary endpoint: Safety: treatment-emergent adverse events. Started Sep 2023; status: completed.
02
Drugs
azacitidine
03
Conditions
Hematopathy
Beyond the preview
Go deeper on 2023-503272-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503272-25-00.